<DOC>
	<DOCNO>NCT02921737</DOCNO>
	<brief_summary>This open-label , non-randomized , sequentially enrol single arm phase II trial evaluate activity TAS-102 previously treat metastatic locally advanced unresectable pancreatic cancer progression intolerance first line chemotherapy . Trial therapy consist TAS-102 ( Lonsurf® ) 35 mg/m2 give orally twice daily day 1-5 8-12 cycle repeat every 28 day . The primary endpoint determine progression free survival ( PFS ) subject unresectable pancreatic adenocarcinoma .</brief_summary>
	<brief_title>TAS-102 ( Lonsurf ) Metastatic Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy ( UF-STO-PANC-003 )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Trifluridine</mesh_term>
	<criteria>Histologic cytologic confirm adenocarcinoma pancreas . Clinically metastatic locally advanced unresectable disease verify radiographic imaging . Documented progression intolerance first line chemotherapy . TAS102 plan start disease progression firstline chemotherapy , provide prior chemotherapyrelated toxicity resolve less equal Grade 1 baseline . Grade 2 great toxicity include alopecia , skin pigmentation , platinum induce neurotoxicity/neuropathy acceptable start trial , toxicity preclude treatment TAS102 ECOG Performance Status 02 Capacity understand sign inform consent document Able take medication orally Life expectancy &gt; 12 week predict treat oncologist 's clinician judgement Age &gt; 18 year Patients childbearing potential must use effective mean contraception include limited barrier method , birth control , intrauterine device . Histologic diagnosis pancreatic cancer treat previously one line chemotherapy . Previous surgery and/or radiotherapy could perform one month prior study enrollment , must evidence disease progression radiographically intolerance firstline chemotherapy . Patients anticoagulation need evidence bleed stable anticoagulation dose least 2 week prior trial enrollment Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study least 6 month last dose study drug minimize risk pregnancy . Prior study enrollment , woman childbearing potential must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . WOCBP include woman experience menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Postmenopause define : Amenorrhea last ≥ 12 consecutive month without another cause , For woman irregular menstrual period take hormone replacement therapy ( HRT ) , document serum folliclestimulating hormone ( FSH ) level great 35 mIU/mL . Males female partner childbearing potential must agree use physicianapproved contraceptive method ( e.g. , abstinence , condom , vasectomy ) throughout study avoid conceive child 4 week follow last dose study drug . Subjects must provide write informed consent willing comply studyrelated procedure . Baseline laboratory value ( bone marrow , renal , hepatic ) must include : Adequate bone marrow function : Absolute neutrophil count &gt; 1500/µL Platelet count &gt; 75,000/µL HGB equal great 7g/dL Renal function : Serum creatinine &lt; 1.5 mg % Hepatic function : Bilirubin &lt; 3.0mg/dL AST ALT equal le 3 time upper limit normal Serum calcium &lt; 12 mg/dl Pregnant lactating female Decline use effective mean contraception sexually active Previously take TAS102 Myocardial infarction ischemia within 6 month study screen Uncontrolled ' clinically significant dysrhythmia No history invasive malignancy within five year prior initiate therapy protocol . Patients may prior situ carcinoma ( breast cervix ) , nonmelanoma skin cancer , Rai Stage 0 chronic lymphocytic leukemia monoclonal gammopathy uncertain significance still otherwise qualify enrollment protocol Radiotherapy target lesion within 2 week Major surgery within prior 4 week ( surgical incision fully heal prior study medication administration ) . Antineoplastic , biologic anticancer treatment within prior 3 week Lingering NCICTCAE toxicity grade 2 high prior cancer treatment ( exclude alopecia , skin pigmentation , platinum induced neurotoxicity ) Any co morbid condition ' view attend physician ' render patient high risk treatment complication include limited chronic infection , uncontrolled diabetes , congestive heart failure accord NYHA criterion , untreated brain metastasis , liver renal failure , gastrointestinal hemorrhage . Patients severe hepatic enzyme impairment manifest total bilirubin great 3.0mg/dL great 3 time upper limit normal AST ALT Known brain metastasis leptomeningeal disease Active infection ( i.e. , body temperature &gt; equal 38degrees C due infection ) Other concurrently active malignancy exclude malignancy disease free 5 year carcinomainsitu deem cured adequate treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>metastatic</keyword>
	<keyword>pancreatic</keyword>
	<keyword>adenocarcinoma</keyword>
</DOC>